Zobrazeno 1 - 10
of 368
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastián Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean O’Donnell, Filippo de Marinis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients w
Externí odkaz:
https://doaj.org/article/6e906fdccdde435787415eaa66c8249f
Autor:
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 10033-10042 (2023)
Background: ALK tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and largely improved the survival outcomes of patients with NSCLC harboring ALK rearrangements. Different ALK TKI compounds have demonstrated antitumor activity in th
Externí odkaz:
https://doaj.org/article/54f230401afe47b6b58e03ea5df5f95f
Autor:
Pamela Trillo Aliaga, Ester Del Signore, Valeria Fuorivia, Gianluca Spitaleri, Riccardo Asnaghi, Ilaria Attili, Carla Corvaja, Ambra Carnevale Schianca, Antonio Passaro, Filippo de Marinis
Publikováno v:
Genes, Vol 15, Iss 6, p 701 (2024)
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma accounting for 15% of lung cancers with dismal survival outcomes. Minimal changes in therapy and prognosis have occurred in SCLC for the past four decades. Recent progress in the
Externí odkaz:
https://doaj.org/article/cb99cc0e1f1d4a489f82cfd55b51442e
Autor:
Robert Johnston, Hartmut Koeppen, Roy S Herbst, Kurt Schalper, Filippo De Marinis, Giuseppe Giaccone, Jacek Jassem, Marcus Ballinger, Barani Kumar Rajendran, David R Spigel, Miguel López de Rodas, Minu K Srivastava, Jennifer M Giltnane, Barzin Y Nabet, David S Shames, Velimir Gayevskiy, Vy Ma, Ivette Estay, Tien Hoang, Reena Amin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/49316787c82b4055a76f2b4631e47f3f
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5072-5092 (2023)
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK
Externí odkaz:
https://doaj.org/article/237f3ac30475444a97d7a0d94817d83b
Publikováno v:
Cancers, Vol 16, Iss 7, p 1331 (2024)
Uncommon (ucEGFRmuts) and rare epidermal growth factor receptor (EGFR) mutations account for 10–15% of diagnosed cases and consist of a heterogeneous group represented by several clusters within exons 18–21 (e.g., exon 18 point mutations, exon 21
Externí odkaz:
https://doaj.org/article/c3146ffb663c421694202e048dcc0d49
Autor:
Francesco Petrella, Stefania Rizzo, Ilaria Attili, Antonio Passaro, Thomas Zilli, Francesco Martucci, Luca Bonomo, Filippo Del Grande, Monica Casiraghi, Filippo De Marinis, Lorenzo Spaggiari
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 3160-3175 (2023)
Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases o
Externí odkaz:
https://doaj.org/article/7cd90eff1b2743afa1500462c53fc72d
Autor:
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Ester Del Signore, Pamela Trillo Aliaga, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 15, Iss 20, p 5079 (2023)
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring most driver gene alterations. Starting from the first generation, research rapidly moved to the develo
Externí odkaz:
https://doaj.org/article/4b8767c369a746daa0fdd2eb0f0f8c68
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Jacopo Uliano, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 15, Iss 19, p 4779 (2023)
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. Retrospective studies of surgical series of patients with MET-dysregulated NSCLC h
Externí odkaz:
https://doaj.org/article/90847ff7dadf4c7886b63ffcc5e1eb26
Autor:
Lisa Rinaldi, Elena Guerini Rocco, Gianluca Spitaleri, Sara Raimondi, Ilaria Attili, Alberto Ranghiero, Giulio Cammarata, Marta Minotti, Giuliana Lo Presti, Francesca De Piano, Federica Bellerba, Gianluigi Funicelli, Stefania Volpe, Serena Mora, Cristiana Fodor, Cristiano Rampinelli, Massimo Barberis, Filippo De Marinis, Barbara Alicja Jereczek-Fossa, Roberto Orecchia, Stefania Rizzo, Francesca Botta
Publikováno v:
Cancers, Vol 15, Iss 18, p 4553 (2023)
Non-invasive methods to assess mutational status, as well as novel prognostic biomarkers, are warranted to foster therapy personalization of patients with advanced non-small cell lung cancer (NSCLC). This study investigated the association of contras
Externí odkaz:
https://doaj.org/article/5346dd5ede3a4c708474bf9f1f815e73